Daily Roundup
Friday, 20th November 2026 · updated 12:00
NEXTDC Lifts Guidance Despite M3 Headwinds
Data centre operator NEXTDC is putting a positive spin on a challenging year, upgrading its FY27 net revenue guidance to A$485 million to A$500 million and lifting underlying EBITDA to A$260 million to A$275 million. The upgrades come despite delays to its M3 expansion project, which has been weighing on the company's near-term outlook.
At its annual general meeting, Chairman Doug Smith and CEO Craig Scroggie reassured shareholders that the long-term investment case remains solid. The company is sitting on a substantial contracted pipeline and is focused on converting that capacity into actual revenue and cash flow. While the M3 delay has forced the company to exclude certain contracts from its FY27 guidance, NEXTDC is maintaining its capital expenditure guidance at A$4,500 million to A$5,000 million as it continues to build out its critical infrastructure assets.
The company's fundamentals are being buoyed by strong demand for cloud, AI, and digital transformation services. Recent strategic investments from Goodman Group and Digital Realty—who acquired a combined 9.9% stake—underscore confidence in NEXTDC's portfolio of strategically valuable assets. Management is now focused on strengthening execution and addressing community concerns around the M3 expansion.
Pro Medicus Lands Major NYC Health Deal
Medical imaging software company Pro Medicus has secured a significant 10-year, A$128 million contract with NYC Health + Hospitals, one of the largest public healthcare systems in the United States. The deal will see Pro Medicus' Visage 7 Enterprise Imaging Platform replace legacy systems across the entire network, integrating diagnostic imaging with the hospitals' electronic health records.
The implementation will be cloud-based, with rollout beginning immediately and a go-live date targeted for late Q3 2027. The contract includes Visage 7 Viewer, Workflow, and Open Archive capabilities, and operates on a transaction-based model with potential upside for the company. This win represents a major foothold for Pro Medicus in the US healthcare market.
Duratec Secures Over $200M in New Contracts
Engineering and construction contractor Duratec has landed three new contracts worth more than $200 million, significantly bolstering its order book across the energy and defence sectors. The wins include a four-year integrated maintenance services contract with Santos Limited for its Darwin LNG and Varanus Island operations, a redevelopment contract for the Yongah Hill Immigration Detention Centre, and a fuel fabrication project for the Defence Fuels Resilience Program at RAAF Base Learmonth.
These contracts provide Duratec with long-term revenue visibility and expand its presence in strategically important sectors.
Vection Technologies Pursues US Expansion Through zSpace Acquisition
Vection Technologies is making a strategic push into the US market with plans to acquire zSpace, Inc., an AR/VR education technology company, for approximately A$13.6 million. To fund the acquisition and integration costs, Vection is raising A$5.0 million in capital.
The deal aims to unlock zSpace's potential by removing its debt burden and capital constraints, while allowing Vection to expand its footprint in the US market. The capital raising will also support AI and XR integration efforts, as well as sales and marketing expansion.
Monash IVF Flags Challenging Year Ahead
Monash IVF Group has issued a trading update signalling headwinds for FY27. The Australian stimulated-cycle market contracted by 3.2% in the first quarter, and while Monash maintained its market share at 19.4%, the company faces increased fixed costs and supplier price hikes that are weighing on earnings quality.
The company expects its underlying FY27 net profit after tax to be materially below FY26 and current analyst consensus estimates. However, Monash is pushing ahead with a structural productivity transformation program designed to deliver A$8 million to A$11 million in annualised savings, though these benefits are expected to materialise over a longer timeframe. The outlook assumes no significant improvement in market activity during the second half of the financial year.
References
-
NXT
79
FY27 Guidance Upgrade
-
PME
78
PME signs 10-year deal, A$128M with NYC Health and Hospitals
-
DUR
72
DURATEC SECURES OVER $200M IN CONTRACT AWARDS
-
VR1
69
USA acquisition and Capital Raising Investor Presentation
-
MVF
67
FY27 Trading Update
-
NXT
65
2026 AGM Chairman & CEO Presentation
-
NXT
65
2026 AGM Presentation